Evidence method
Sequential · gp.financial.deposits
-1.07% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
PEBO · Sep 30, 2022
PEOPLES BANCORP INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000318300-22-000302Bank
Evidence method
Level · gp.fundamentals.cash
$145.2M · CORE · VALID
Evidence method
Sequential · gp.financial.loans
0.77% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History24 statesSelf-history eligible
Sep 30, 20210/3 normalizedLevel 3Dec 31, 20210/6 normalizedLevel 3Mar 31, 20220/6 normalizedLevel 3Jun 30, 20221/6 normalizedLevel 3Sep 30, 20223/3 normalizedLevel 3Dec 31, 20223/6 normalizedLevel 3Mar 31, 20233/6 normalizedLevel 3Jun 30, 20233/6 normalizedLevel 3Sep 30, 20233/6 normalizedLevel 3Dec 31, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20245/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20245/5 normalizedLevel 3Mar 31, 20255/5 normalizedLevel 3Jun 30, 20255/5 normalizedLevel 3Sep 30, 20255/5 normalizedLevel 3Dec 31, 20255/5 normalizedLevel 3Mar 31, 20265/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -1.23%
- Current
- -1.07%
- Delta
- 0.16%
- Previous
- $398.4M
- Current
- $145.2M
- Delta
- -$253.2M
- Previous
- 0.69%
- Current
- 0.77%
- Delta
- 0.07%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.